Who are semaglutide or tirzepatide's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Mounjaro, Ozempic, Trulicity, iGlarLixi, Insulin glargine/Lixisenatide, glargine + exenatide.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/semaglutide-or-tirzepatide.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

semaglutide or tirzepatide — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

semaglutide or tirzepatide (semaglutide or tirzepatide) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: GLP-1 receptor agonist. Area: Metabolic.

marketed GLP-1 receptor agonist GLP-1 receptor Metabolic Small molecule Live · refreshed every 30 min

Target snapshot

semaglutide or tirzepatide (semaglutide or tirzepatide) — Mayo Clinic. Semaglutide and tirzepatide are GLP-1 receptor agonists that enhance glucose-dependent insulin secretion and reduce glucagon secretion, leading to improved glycemic control and weight loss.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
semaglutide or tirzepatide TARGET	semaglutide or tirzepatide	Mayo Clinic	marketed	GLP-1 receptor agonist	GLP-1 receptor
Mounjaro	TIRZEPATIDE	Eli Lilly	marketed	Dual GIP/GLP-1 receptor agonist	GIP receptor and GLP-1 receptor	2022-01-01
Ozempic	semaglutide	Novo Nordisk	marketed	GLP-1 Receptor Agonist [EPC]	GLP-1 receptor	2017-01-01
Trulicity	DULAGLUTIDE	Eli Lilly	marketed	GLP-1 Receptor Agonist [EPC]	GLP-1 receptor	2014-01-01
iGlarLixi	iGlarLixi	The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School	marketed	Insulin/GLP-1 receptor agonist combination	Insulin receptor; GLP-1 receptor
Insulin glargine/Lixisenatide	Insulin glargine/Lixisenatide	Sanofi	marketed	Insulin/GLP-1 receptor agonist combination	Insulin receptor; GLP-1 receptor
glargine + exenatide	glargine + exenatide	Huazhong University of Science and Technology	marketed	Basal insulin + GLP-1 receptor agonist combination	Insulin receptor (glargine); GLP-1 receptor (exenatide)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2026-07-17 — Ozempic · 11097063 · US
2026-07-17 — Ozempic · 8920383 · US
2026-07-17 — Ozempic · 9775953 · US
2026-07-17 — Ozempic · 10220155 · US
2026-08-03 — Ozempic · RE46363 · US
2027-02-27 — Ozempic · 9687611 · US
2027-09-27 — Ozempic · 9457154 · US
2031-12-05 — Ozempic · 8129343 · US
2031-12-16 — Ozempic · 10960052 · US
2031-12-16 — Ozempic · 9278123 · US
2031-12-16 — Ozempic · 10086047 · US
2031-12-16 — Ozempic · 11382957 · US
2032-02-01 — Ozempic · 9132239 · US
2033-03-15 — Ozempic · 10933120 · US
2033-06-21 — Ozempic · 9764003 · US
2033-06-21 — Ozempic · 10335462 · US
2034-05-02 — Ozempic · 10278923 · US
2034-06-15 — semaglutide or tirzepatide · US9662337B2 · US
2034-06-15 — semaglutide or tirzepatide · US9290477B2 · US
2038-08-24 — Ozempic · 10888605 · US
2041-02-17 — Ozempic · 11318191 · US

Sponsor landscape (GLP-1 receptor agonist class)

Hanmi Pharmaceutical Company Limited · 30 drugs in this class
Eli Lilly and Company · 8 drugs in this class
Novo Nordisk A/S · 6 drugs in this class
GlaxoSmithKline · 6 drugs in this class
Sanofi · 4 drugs in this class
AstraZeneca · 4 drugs in this class
Daewoong Pharmaceutical Co. LTD. · 4 drugs in this class
Hangzhou Sciwind Biosciences Co., Ltd. · 3 drugs in this class
Jiangsu Hansoh Pharmaceutical Co., Ltd. · 2 drugs in this class
Huons Co., Ltd. · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). semaglutide or tirzepatide — Competitive Intelligence Brief. https://druglandscape.com/ci/semaglutide-or-tirzepatide. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab